• Explore /
  • Poster
  • / Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.

Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.

Abstract Video & Slides Poster

Authors

Erika Hamilton

Erika Paige Hamilton

Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Erika Paige Hamilton , Thierry Petit , Barbara Pistilli , Anthony Goncalves , Ana Alexandra Ferreira , Florence Dalenc , Fatima Cardoso , Monica M. Mita , Vincent O. Dezentjé , Luis Manso , Stephanie L. Graff , Francois Clement Bidard , Philippe Georges Aftimos , Santiago Escrivá , Noemia Afonso , Ernesto Wasserman , Kees Bol , Viktoriya Stalbovskaya , Anastasia Vliet , Thomas Bachelot

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT03321981

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3093)

DOI

10.1200/JCO.2020.38.15_suppl.3093

Abstract #

3093

Poster Bd #

157

Abstract Disclosures

Similar Posters

First Author: Cecile Geuijen

First Author: Nicholas Patrick McAndrew

First Author: Maria Alsina

First Author: Edith A. Perez